TY - JOUR
T1 - Glycaemic management in diabetes
T2 - old and new approaches
AU - Ceriello, Antonio
AU - Prattichizzo, Francesco
AU - Phillip, Moshe
AU - Hirsch, Irl B.
AU - Mathieu, Chantal
AU - Battelino, Tadej
N1 - Funding Information:
This work was supported, in part, by the Italian Ministry of Health (Ricerca Corrente) to IRCCS MultiMedica. TB was supported in part by the Slovenian Research Agency ( grant no: P3–0343 ).
Funding Information:
AC is on the advisory board and does consultancy and lectures for AstraZeneca, BERLIN-CHEMIE, Eli Lilly, Novo Nordisk, Mitsubishi, Roche Diagnostics, and Theras Lifetech. FP is a lecturer for BERLIN-CHEMIE. MP has received grants and research support from Medtronic, Novo Nordisk, Roche, Eli Lilly, Sanofi, Pfizer, Insulet, OPKO Health, Dexcom, DreamMed Diabetes, and NG Solutions. MP has received honoraria or consultation fees from Sanofi, Medtronic, Novo Nordisk, Eli Lilly, and Pfizer, and MP is on the advisory board for Sanofi, Medtronic, AstraZeneca, Eli Lilly, Insulet, and Pfizer. MP is a stock shareholder for NG Solutions, DreaMed Diabetes, and is a consultant at QULAB Medical. IBH is a consultant for Abbott Diabetes Care, Big Foot, Roche, GWave, and does research for Medtronic, Insulet, and Beta Bionics. CM serves or has served on the advisory board for Novo Nordisk, Sanofi, Merck Sharp and Dohme, Eli Lilly and Company, Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Medtronic, ActoBio Therapeutics, Pfizer, Insulet, and Zealand Pharma. Financial compensation for these activities has been received by KU Leuven; KU Leuven has received research support for CM from Medtronic, Novo Nordisk, Sanofi and ActoBio Therapeutics. CM serves or has served on the speakers bureau for Novo Nordisk, Sanofi, Eli Lilly and Company, Boehringer Ingelheim, Astra Zeneca, and Novartis. Financial compensation for these activities has been received by KU Leuven. TB served on advisory boards of Novo Nordisk, Sanofi, Eli Lilly, Boehringer, Medtronic, Indigo, and DreaMed Diabetes. TB received honoraria for participating on the speaker's bureaux of Eli Lilly, Novo Nordisk, Medtronic, Abbott, Sanofi, Aventis, Astra Zeneca, and Roche. TB owns stocks of DreamMed Diabetes. TB's institution received research grant support from Abbott, Medtronic, Novo Nordisk, GluSense, Sanofi, Novartis, Sandoz, and Zealand Pharma.
Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2021/11
Y1 - 2021/11
N2 - HbA1c is the most used parameter to assess glycaemic control. However, evidence suggests that the concept of hyperglycaemia has profoundly changed and that different facets of hyperglycaemia must be considered. A modern approach to glycaemic control should focus not only on reaching and maintaining optimal HbA1c concentrations as early as possible, but to also do so by reducing postprandial hyperglycaemia, glycaemic variability, and to extend as much as possible the time in range in near-normoglycaemia. These goals should be achieved while avoiding hypoglycaemia, which, should it occur, should be reverted to normoglycaemia. Modern technology, such as intermittently scanned glucose monitoring and continuous glucose monitoring, together with new drug therapies (eg, ultra-fast insulins, SGLT2 inhibitors, and GLP-1 receptor agonists), could help to change the landscape of glycaemia management based on HbA1c in favour of a more holistic approach that considers all the different aspects of this commonly oversimplified pathophysiological feature of diabetes.
AB - HbA1c is the most used parameter to assess glycaemic control. However, evidence suggests that the concept of hyperglycaemia has profoundly changed and that different facets of hyperglycaemia must be considered. A modern approach to glycaemic control should focus not only on reaching and maintaining optimal HbA1c concentrations as early as possible, but to also do so by reducing postprandial hyperglycaemia, glycaemic variability, and to extend as much as possible the time in range in near-normoglycaemia. These goals should be achieved while avoiding hypoglycaemia, which, should it occur, should be reverted to normoglycaemia. Modern technology, such as intermittently scanned glucose monitoring and continuous glucose monitoring, together with new drug therapies (eg, ultra-fast insulins, SGLT2 inhibitors, and GLP-1 receptor agonists), could help to change the landscape of glycaemia management based on HbA1c in favour of a more holistic approach that considers all the different aspects of this commonly oversimplified pathophysiological feature of diabetes.
UR - http://www.scopus.com/inward/record.url?scp=85120413682&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120413682&partnerID=8YFLogxK
U2 - 10.1016/S2213-8587(21)00245-X
DO - 10.1016/S2213-8587(21)00245-X
M3 - Review article
C2 - 34793722
AN - SCOPUS:85120413682
SN - 2213-8587
VL - 10
SP - 75
EP - 84
JO - The Lancet Diabetes and Endocrinology
JF - The Lancet Diabetes and Endocrinology
IS - 1
ER -